Related Projects

The AutoCRAT team have close connections with other projects and initiatives working in regenerative medicine and life sciences engineering. Some of these initiatives are set out below.

AUTOSTEM logo

AUTOSTEM: The full title of the AUTOSTEM Project was “Development of closed, scalable and automated robotic systems for therapeutic stem cell manufacturing: aseptic systems from Donor-to-Patient”. AUTOSTEM was a H2020 EU funded project which ran from 1 January 2016 to 31 December 2018. AUTOSTEM and AutoCRAT have some common partners and AUTOSTEM will form an important building block for the AutoCRAT Regenerative Medicine Factory (ARM-F). Prof. Mary Murphy of NUIG (Coordinator of AutoCRAT) was also the Coordinator of AUTOSTEM.

ADIPOA-2 logo

ADIPOA 2: This EU H2020 Project is carrying out a phase IIb study to assess the safety and efficacy of autologous (patient-derived) mesenchymal stromal cells in the treatment of advanced OA of the knee. The Project runs from 1 January 2015 to 31 December 2019. ADIPOA-2 and AutoCRAT have some common partners. NUIG is Coordinator.

VISICORT logo

VISICORT: This EU H2020 Project explores the use of stromal cell therapy for the prevention of adverse immune responses in recipients of high-risk corneal transplants. The Project runs from 1 April 2014 to 30 September 2020 and shares some common partners with AutoCRAT. NUIG is Coordinator.

NEPHSTROM logo

NEPHSTROM: This EU H2020 Project explores the treatment of diabetic kidney disease with a purified population of Mesenchymal Stromal Cells (MSCs) from human bone marrow. The Project runs from 1 May 2015 to 31 October 2020 and has some common partners with AutoCRAT. NUIG is Coordinator.

STARSTEM logo

STARSTEM: This EU H2020 Project is using fundamental advances in the physics of imaging to validate stem cell treatments for arthritis. STARSTEM runs from 1 January 2018 to 31 December 2021 and shares common partners with AutoCRAT. NUIG is Coordinator.

 

STEMCELLFACTORY III logo

STEMCELLFACTORY III: This project is funded through the European Regional Development Fund and is developing methods for the automated production of patient- and disease-specific induced pluripotent stem cells (iPS cells) from easy-to-obtain blood samples. The Project runs from 1 July 2017 to 30 June 2020 and is coordinated by AutoCRAT partner Fraunhofer IPT.